Cardinal Health (NYSE:CAH - Get Free Report) had its price target raised by research analysts at Bank of America from $150.00 to $155.00 in a note issued to investors on Friday,Benzinga reports. The firm presently has a "buy" rating on the stock. Bank of America's target price would suggest a potential upside of 14.90% from the company's current price.
A number of other analysts also recently weighed in on CAH. Citigroup increased their price target on Cardinal Health from $120.00 to $129.00 and gave the stock a "neutral" rating in a report on Friday, January 10th. Mizuho lifted their price objective on shares of Cardinal Health from $142.00 to $150.00 and gave the company an "outperform" rating in a research note on Monday, March 31st. Jefferies Financial Group upgraded shares of Cardinal Health from a "hold" rating to a "buy" rating and raised their price target for the stock from $140.00 to $150.00 in a report on Wednesday, February 5th. Argus set a $148.00 price objective on shares of Cardinal Health in a research report on Tuesday, February 4th. Finally, Wells Fargo & Company boosted their target price on Cardinal Health from $135.00 to $136.00 and gave the company an "equal weight" rating in a research report on Tuesday, February 4th. Four research analysts have rated the stock with a hold rating and eleven have given a buy rating to the stock. Based on data from MarketBeat, the stock has a consensus rating of "Moderate Buy" and an average target price of $140.86.
Read Our Latest Analysis on Cardinal Health
Cardinal Health Stock Up 0.5 %
Shares of CAH stock traded up $0.65 during mid-day trading on Friday, reaching $134.90. 1,273,483 shares of the stock traded hands, compared to its average volume of 2,180,970. The stock's fifty day simple moving average is $129.62 and its two-hundred day simple moving average is $122.74. The company has a market cap of $32.59 billion, a price-to-earnings ratio of 25.17, a price-to-earnings-growth ratio of 1.49 and a beta of 0.61. Cardinal Health has a 1-year low of $93.17 and a 1-year high of $139.50.
Cardinal Health (NYSE:CAH - Get Free Report) last released its quarterly earnings results on Thursday, January 30th. The company reported $1.93 EPS for the quarter, beating analysts' consensus estimates of $1.74 by $0.19. Cardinal Health had a negative return on equity of 59.57% and a net margin of 0.59%. On average, equities research analysts anticipate that Cardinal Health will post 7.95 EPS for the current fiscal year.
Hedge Funds Weigh In On Cardinal Health
Several institutional investors and hedge funds have recently bought and sold shares of the company. Fort Washington Investment Advisors Inc. OH lifted its position in shares of Cardinal Health by 0.8% during the 1st quarter. Fort Washington Investment Advisors Inc. OH now owns 11,981 shares of the company's stock valued at $1,651,000 after buying an additional 98 shares during the last quarter. Yarger Wealth Strategies LLC bought a new stake in Cardinal Health in the 1st quarter valued at about $242,000. Fifth Third Bancorp lifted its holdings in Cardinal Health by 5.4% during the first quarter. Fifth Third Bancorp now owns 14,190 shares of the company's stock valued at $1,955,000 after purchasing an additional 732 shares during the last quarter. Visionary Horizons LLC bought a new position in Cardinal Health during the first quarter worth about $640,000. Finally, Transform Wealth LLC increased its stake in shares of Cardinal Health by 75.0% in the first quarter. Transform Wealth LLC now owns 17,715 shares of the company's stock worth $2,441,000 after purchasing an additional 7,591 shares in the last quarter. 87.17% of the stock is owned by institutional investors.
Cardinal Health Company Profile
(
Get Free Report)
Cardinal Health, Inc operates as a healthcare services and products company in the United States, Canada, Europe, Asia, and internationally. It provides customized solutions for hospitals, healthcare systems, pharmacies, ambulatory surgery centers, clinical laboratories, physician offices, and patients in the home.
See Also
Before you consider Cardinal Health, you'll want to hear this.
MarketBeat keeps track of Wall Street's top-rated and best performing research analysts and the stocks they recommend to their clients on a daily basis. MarketBeat has identified the five stocks that top analysts are quietly whispering to their clients to buy now before the broader market catches on... and Cardinal Health wasn't on the list.
While Cardinal Health currently has a Moderate Buy rating among analysts, top-rated analysts believe these five stocks are better buys.
View The Five Stocks Here
Wondering what the next stocks will be that hit it big, with solid fundamentals? Enter your email address to see which stocks MarketBeat analysts could become the next blockbuster growth stocks.
Get This Free Report
Like this article? Share it with a colleague.
Link copied to clipboard.
